AV 1101

Drug Profile

AV 1101

Latest Information Update: 06 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator A-Viral ASA
  • Developer A-Viral NL BV
  • Class Anti-inflammatories; Antirheumatics; Antivirals; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections; Inflammation; Rheumatoid arthritis; Skin disorders

Most Recent Events

  • 06 Feb 2017 Discontinued - Phase-II for HIV infections treatment in Philippines (unspecified route)
  • 06 Feb 2017 Discontinued - Phase-II for Inflammation in Netherlands (unspecified route)
  • 06 Feb 2017 Discontinued - Phase-II for Rheumatoid arthritis in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top